Login | Users Online: 15403  
Home Print this page Email this page Small font sizeDefault font sizeIncrease font size   
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contact us

    Article Cited by others


Ranolazine: Multifaceted role beyond coronary artery disease, a recent perspective

Ghosh Gopal Chandra, Ghosh Raktim Kumar, Bandyopadhyay Dhrubajyoti, Chatterjee Krishnarpan, Aneja Ashish

Year : 2018| Volume: 19| Issue : 3 | Page no: 88-98

   This article has been cited by
1 From Energy Metabolic Change to Precision Therapy: a Holistic View of Energy Metabolism in Heart Failure
Jianpei Wen, Chen Chen
Journal of Cardiovascular Translational Research. 2023;
[Pubmed]  [Google Scholar] [DOI]
2 Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction
Randall P. Sharp,Edna Patatanian,Riaz Sirajuddin
American Journal of Cardiovascular Drugs. 2021;
[Pubmed]  [Google Scholar] [DOI]
3 “Pill in the Pocket” Antiarrhythmic Drugs for Orally Administered Pharmacologic Cardioversion of Atrial Fibrillation
James A. Reiffel,Alessandro Capucci
The American Journal of Cardiology. 2021; 140: 55
[Pubmed]  [Google Scholar] [DOI]
4 Phospho-ablation of cardiac sodium channel Nav1.5 mitigates susceptibility to atrial fibrillation and improves glucose homeostasis under conditions of diet-induced obesity
Revati S. Dewal,Amara Greer-Short,Cemantha Lane,Shinsuke Nirengi,Pedro Acosta Manzano,Diego Hernández-Saavedra,Katherine R. Wright,Drew Nassal,Lisa A. Baer,Peter J. Mohler,Thomas J. Hund,Kristin I. Stanford
International Journal of Obesity. 2021; 45(4): 795
[Pubmed]  [Google Scholar] [DOI]
5 Diabetogenic effects of cardioprotective drugs
David S.H. Bell,Edison Goncalves
Diabetes, Obesity and Metabolism. 2021; 23(4): 877
[Pubmed]  [Google Scholar] [DOI]


Read this article